scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1050046323 |
P356 | DOI | 10.1186/S12937-015-0072-6 |
P932 | PMC publication ID | 4538921 |
P698 | PubMed publication ID | 26283663 |
P5875 | ResearchGate publication ID | 281141921 |
P50 | author | Jordan E Lake | Q98905399 |
Sandra Wagner Cardoso | Q117256309 | ||
Beatriz Grinsztejn | Q60246105 | ||
Valdiléa G Veloso | Q60637563 | ||
Risa Hoffman | Q89630094 | ||
Judith S Currier | Q92484240 | ||
P2093 | author name string | Paula M Luz | |
Lara Coelho | |||
Laura Mendonça | |||
P2860 | cites work | Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline | Q22306207 |
Update in vitamin D | Q22306211 | ||
25-hydroxyvitamin D levels and the risk of mortality in the general population | Q24650811 | ||
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes | Q33997476 | ||
Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. | Q34340891 | ||
Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen | Q34403352 | ||
Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women | Q35019046 | ||
Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings | Q35154069 | ||
HDL cholesterol and bone mineral density: is there a genetic link? | Q35608491 | ||
Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection | Q36361380 | ||
A potential role for vitamin D on HIV infection? | Q36505204 | ||
Interplay between vitamin D and the drug metabolizing enzyme CYP3A4 | Q36545257 | ||
Cross-sectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults. | Q36736469 | ||
Vitamin D in HIV-Infected Patients | Q36884537 | ||
Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000 | Q36906320 | ||
Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth | Q37029416 | ||
Prevalence of vitamin D deficiency during the summer and its relationship with sun exposure and skin phototype in elderly men living in the tropics | Q37225445 | ||
Vitamin D deficiency is associated with development of subclinical coronary artery disease in HIV-infected African American cocaine users with low Framingham-defined cardiovascular risk | Q37324416 | ||
Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals | Q37492503 | ||
Vitamin D status among healthy postmenopausal women in South America | Q37499904 | ||
Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial | Q37504465 | ||
Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART. | Q37518789 | ||
Less than adequate vitamin D status and intake in Latin America and the Caribbean:a problem of unknown magnitude. | Q38114458 | ||
Correlation between 25-hydroxyvitamin D levels and latitude in Brazilian postmenopausal women: from the Arzoxifene Generations Trial | Q38878333 | ||
HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. | Q40668951 | ||
Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy | Q41606828 | ||
Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density | Q41684650 | ||
Association of vitamin D levels, lipid profile and intima media thickness in HIV positive patients | Q41968927 | ||
Factors associated with vitamin D deficiency in a population of 2044 HIV-infected patients | Q42262759 | ||
Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. | Q43001305 | ||
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients | Q43157193 | ||
1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. | Q43775059 | ||
Bone mineral density, metabolic syndrome, and vitamin D in indigenous from south of Brazil | Q44177746 | ||
Relation among micronutrient intakes with CD4 count in HIV infected patients | Q44270537 | ||
Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults | Q44580359 | ||
High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. | Q44585706 | ||
Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital | Q45117160 | ||
Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey | Q45161552 | ||
Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis | Q45752853 | ||
Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival | Q45783304 | ||
Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis | Q46042022 | ||
Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism | Q46101041 | ||
Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy | Q46543775 | ||
Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. | Q51678383 | ||
Correlation of Increases in 1,25-Dihydroxyvitamin D During Vitamin D Therapy With Activation of CD4+ T Lymphocytes in HIV-1–Infected Males | Q60291318 | ||
Prevalence and correlates of calcium and vitamin D status adequacy in adolescents, adults, and elderly from the Health Survey—São Paulo | Q61766893 | ||
Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N | Q80217296 | ||
P921 | main subject | cholecalciferol | Q139347 |
anti-retroviral agent | Q50430310 | ||
P304 | page(s) | 81 | |
P577 | publication date | 2015-08-18 | |
P1433 | published in | Nutrition Journal | Q15751205 |
P1476 | title | Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy | |
P478 | volume | 14 |
Q38844898 | Cholecalciferol 20 000 IU Once Weekly in HIV-Positive Patients with Low Vitamin D Levels: Result from a Cohort Study |
Q54224147 | Continued Interest and Controversy: Vitamin D in HIV. |
Q61798245 | Daily Nutritional Supplementation with Vitamin D₃ and Phenylbutyrate to Treatment-Naïve HIV Patients Tested in a Randomized Placebo-Controlled Trial |
Q62489966 | Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial |
Q38978858 | Effects of cholecalciferol supplementation on serum and urinary vitamin D metabolites and binding protein in HIV-infected youth |
Q40112514 | Mechanisms of action of vitamin D as supplemental therapy for Pneumocystis pneumonia |
Q33761301 | Micronutrient supplementation in adults with HIV infection. |
Q58770234 | Monthly or Weekly Supplementation with Cholecalciferol 20,000 IU in People Living with HIV: Results from a Nested Cohort Study |
Q40563423 | Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study |
Q38610901 | Role of vitamin D in cytotoxic T lymphocyte immunity to pathogens and cancer |
Q90705218 | The Potential Protective Role of Vitamin D Supplementation on HIV-1 Infection |
Q40375467 | The role of UV radiation and vitamin D in the seasonality and outcomes of infectious disease. |
Q47159869 | Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation |
Q39026377 | Vitamin D and Infectious Diseases: Simple Bystander or Contributing Factor? |
Q36816930 | Vitamin D and bone loss in HIV |
Q55283531 | Vitamin D in Human Immunodeficiency Virus Infection: Influence on Immunity and Disease. |
Q64235744 | Vitamin D in malaria: more hypotheses than clues |
Q26746990 | Vitamin D-Regulated MicroRNAs: Are They Protective Factors against Dengue Virus Infection? |
Q54574587 | [Vitamin D : More than just a bone hormone]. |
Search more.